TABLE 1.
Variations of intravenous antibiotic consumption during a before-and-after intervention trial that replaced CEP with piperacillin-tazobactam
| Antibiotic | Consumption (DDD/1,000 patient-days)a
|
Pb | |
|---|---|---|---|
| Period 1 (baseline) | Period 2 (intervention) | ||
| Amikacin | 20.91 | 17.64 | NS |
| Aminopenicillin-sulbactam | 28.74 | 15.58 | 0.03 |
| Carbapenem | 1.91 | 2.49 | NS |
| Ceftazidime | 17.73 | 1.14 | <0.0001 |
| Ceftriaxone | 12.67 | 5.67 | NS |
| Cephalotin | 30.98 | 32.91 | NS |
| Ciprofloxacin | 11.13 | 22.7 | NS |
| Clarithromycin | 2.42 | 1.17 | NS |
| Clindamycin | 18.27 | 22.75 | NS |
| Gentamicin | 26.06 | 35.93 | NS |
| Metronidazole | 10.08 | 12.53 | NS |
| Piperacillin-tazobactam | 0 | 30.57 | <0.0001 |
| Vancomycin | 8.35 | 9.83 | NS |
| Total | 193.8 | 210.91 | NS |
a
See study design in the text for details.
b
As determined by chi-square test for period 1 versus period 2. Differences between periods were analyzed by comparison of consumption of every drug with respect to the total antibiotic consumption (i.e., the variation in the relative consumption). NS, not significant.